| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Nika De Wilde, Luisa Vonghia, Sven Francque, Thomas De Somer, Ali Bagdadi, Eva Staub, Jasper Lambrechts, Ana-Maria Bucalau, Gontran Verset and Christophe Van Steenkiste |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Gontran Verset, MMed, Doctor, Doctor, Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, Brussels 1070, Belgium. gontran.verset@erasme.ulb.ac.be |
| Key Words |
Advanced hepatocellular carcinoma; Systemic treatment; Immunotherapy; Nivolumab; Difficult-to-treat patients; Real-life setting |
| Core Tip |
We conducted a study on the real-world effectiveness of nivolumab (immunotherapy) in patients with advanced liver cancer who were ineligible for the standard of care or other validated treatments, including patients with impaired liver function and a poor general condition, a population that is usually not included in studies. We showed a reduction of tumor mass in 24.1% of patients, with a disappearance of tumor mass in 13.9% of patients, which is better than that reported in the literature. Furthermore, we confirmed the favorable safety profile of nivolumab. Hence, nivolumab should be considered as a valuable treatment option in selected patients who are otherwise not eligible for treatment. |
| Publish Date |
2022-08-26 09:51 |
| Citation |
De Wilde N, Vonghia L, Francque S, De Somer T, Bagdadi A, Staub E, Lambrechts J, Bucalau AM, Verset G, Van Steenkiste C. Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma. World J Hepatol 2022; 14(8): 1608-1620 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i8/1608.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i8.1608 |
